BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 26759334)

  • 21. Determinants associated with bone mineral density increase in response to daily teriparatide treatment in patients with osteoporosis.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Bone; 2014 Sep; 66():26-30. PubMed ID: 24909538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
    Senn C; Günther B; Popp AW; Perrelet R; Hans D; Lippuner K
    Osteoporos Int; 2014 Jul; 25(7):1945-51. PubMed ID: 24760244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ANABOLIC BONE WINDOW WITH WEEKLY TERIPARATIDE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS: A PILOT STUDY.
    Gopalaswamy V; Dhibar DP; Gupta V; Arya AK; Khandelwal N; Bhansali A; Garg SK; Agarwal N; Rao SD; Bhadada SK
    Endocr Pract; 2017 Jun; 23(6):657-661. PubMed ID: 28225309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
    Deng J; Feng Z; Li Y; Pan T; Li Q; Zhao C
    Medicine (Baltimore); 2018 Nov; 97(47):e13341. PubMed ID: 30461654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.
    Miyauchi A; Matsumoto T; Shigeta H; Tsujimoto M; Thiebaud D; Nakamura T
    J Bone Miner Metab; 2008; 26(6):624-34. PubMed ID: 18979163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study.
    Matsumoto T; Shiraki M; Hagino H; Iinuma H; Nakamura T
    Osteoporos Int; 2006 Oct; 17(10):1532-8. PubMed ID: 16767525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
    J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.
    Cohen A; Stein EM; Recker RR; Lappe JM; Dempster DW; Zhou H; Cremers S; McMahon DJ; Nickolas TL; Müller R; Zwahlen A; Young P; Stubby J; Shane E
    J Clin Endocrinol Metab; 2013 May; 98(5):1971-81. PubMed ID: 23543660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.
    Miller PD; Schwartz EN; Chen P; Misurski DA; Krege JH
    Osteoporos Int; 2007 Jan; 18(1):59-68. PubMed ID: 17013567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis.
    Farahmand P; Marin F; Hawkins F; Möricke R; Ringe JD; Glüer CC; Papaioannou N; Minisola S; Martínez G; Nolla JM; Niedhart C; Guañabens N; Nuti R; Martín-Mola E; Thomasius F; Peña J; Graeff C; Kapetanos G; Petto H; Gentzel A; Reisinger A; Zysset PK
    Osteoporos Int; 2013 Dec; 24(12):2971-81. PubMed ID: 23740422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Twice-weekly teriparatide improves lumbar spine BMD independent of pre-treatment BMD and bone turnover marker levels.
    Takada J; Yoshimura T; Uzawa T
    J Bone Miner Metab; 2021 May; 39(3):484-493. PubMed ID: 33389132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PINP as an aid for monitoring patients treated with teriparatide.
    Tsujimoto M; Chen P; Miyauchi A; Sowa H; Krege JH
    Bone; 2011 Apr; 48(4):798-803. PubMed ID: 21168536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
    Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.
    Finkelstein JS; Leder BZ; Burnett SM; Wyland JJ; Lee H; de la Paz AV; Gibson K; Neer RM
    J Clin Endocrinol Metab; 2006 Aug; 91(8):2882-7. PubMed ID: 16684825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.